000 | 01936 a2200529 4500 | ||
---|---|---|---|
005 | 20250514042654.0 | ||
264 | 0 | _c20030206 | |
008 | 200302s 0 0 eng d | ||
022 | _a0300-7995 | ||
024 | 7 |
_a10.1185/030079902125000787 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aAthyros, Vasilios G | |
245 | 0 | 0 |
_aTreatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. _h[electronic resource] |
260 |
_bCurrent medical research and opinion _c2002 |
||
300 |
_a220-8 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAnalysis of Variance |
650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
650 | 0 | 4 | _aAtorvastatin |
650 | 0 | 4 |
_aCholesterol, HDL _xblood |
650 | 0 | 4 |
_aCholesterol, LDL _xblood |
650 | 0 | 4 |
_aCholesterol, VLDL _xblood |
650 | 0 | 4 |
_aCoronary Disease _xblood |
650 | 0 | 4 | _aCost-Benefit Analysis |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aGreece |
650 | 0 | 4 |
_aHeptanoic Acids _xtherapeutic use |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNational Health Programs |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 |
_aPyrroles _xtherapeutic use |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTriglycerides _xblood |
700 | 1 | _aPapageorgiou, Athanasios A | |
700 | 1 | _aMercouris, Bodosakis R | |
700 | 1 | _aAthyrou, Valasia V | |
700 | 1 | _aSymeonidis, Athanasios N | |
700 | 1 | _aBasayannis, Elias O | |
700 | 1 | _aDemitriadis, Dimokritos S | |
700 | 1 | _aKontopoulos, Athanasios G | |
773 | 0 |
_tCurrent medical research and opinion _gvol. 18 _gno. 4 _gp. 220-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1185/030079902125000787 _zAvailable from publisher's website |
999 |
_c12082968 _d12082968 |